scholarly journals Metastatic pathway-specific transcriptome analysis identifies MFSD4 as a putative tumor suppressor and biomarker for hepatic metastasis in patients with gastric cancer

Oncotarget ◽  
2016 ◽  
Vol 7 (12) ◽  
pp. 13667-13679 ◽  
Author(s):  
Mitsuro Kanda ◽  
Dai Shimizu ◽  
Haruyoshi Tanaka ◽  
Masahiro Shibata ◽  
Naoki Iwata ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Tumor Suppressor ◽  
Hepatic Metastasis ◽  
Transcriptome Analysis ◽  
Putative Tumor Suppressor ◽  
Metastatic Pathway

Zinc-finger protein 331, a novel putative tumor suppressor, suppresses growth and invasiveness of gastric cancer

Oncogene ◽  
2012 ◽  
Vol 32 (3) ◽  
pp. 307-317 ◽  
Author(s):  
J Yu ◽  
Q Y Liang ◽  
J Wang ◽  
Y Cheng ◽  
S Wang ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Tumor Suppressor ◽  
Zinc Finger ◽  
Zinc Finger Protein ◽  
Finger Protein ◽  
Putative Tumor Suppressor

scholarly journals VEZT, a Novel Putative Tumor Suppressor, Suppresses the Growth and Tumorigenicity of Gastric Cancer

PLoS ONE ◽  
2013 ◽  
Vol 8 (9) ◽  
pp. e74409 ◽  
Author(s):  
Ruizhen Miao ◽  
Xiaobo Guo ◽  
Qiaoming Zhi ◽  
Yulong Shi ◽  
Leping Li ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Tumor Suppressor ◽  
Putative Tumor Suppressor

scholarly journals LRRC3B, Encoding a Leucine-Rich Repeat-Containing Protein, Is a Putative Tumor Suppressor Gene in Gastric Cancer

2008 ◽  
Vol 68 (17) ◽  
pp. 7147-7155 ◽  
Author(s):  
Mirang Kim ◽  
Jeong-Hwan Kim ◽  
Hay-Ran Jang ◽  
Hwan-Mook Kim ◽  
Chang-Woo Lee ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Tumor Suppressor ◽  
Tumor Suppressor Gene ◽  
Suppressor Gene ◽  
Leucine Rich Repeat ◽  
Putative Tumor Suppressor Gene ◽  
Putative Tumor Suppressor

scholarly journals Zinc Finger Protein 331, a Novel Putative Tumor Suppressor, Suppresses Growth and Invasiveness of Gastric Cancer Cells

2011 ◽  
Vol 140 (5) ◽  
pp. S-818-S-819
Author(s):  
Jun Yu ◽  
Jia Wang ◽  
Qiaoyi Liang ◽  
Kin-Fai Cheung ◽  
Shiyan Wang ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Tumor Suppressor ◽  
Cancer Cells ◽  
Zinc Finger ◽  
Zinc Finger Protein ◽  
Gastric Cancer Cells ◽  
Finger Protein ◽  
Putative Tumor Suppressor

scholarly journals HIFU for the treatment of gastric cancer with liver metastases with unsuitable indications for hepatectomy and radiofrequency ablation: a prospective and propensity score-matched study

BMC Surgery ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Bin Zhou ◽  
Ning He ◽  
Jiaze Hong ◽  
Tong Yang ◽  
Derry Minyao Ng ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Radiofrequency Ablation ◽  
Propensity Score ◽  
Adverse Events ◽  
Liver Metastases ◽  
Hepatic Metastasis ◽  
Focused Ultrasound ◽  
Progression Free Survival ◽  
High Intensity Focused Ultrasound ◽  
Entire Cohort

Abstract Background The purpose of this study was to explore the efficacy and safety of high intensity focused ultrasound (HIFU) in gastric cancer with liver metastasis (GCLM) patients who were contraindicated for either hepatectomy or radiofrequency ablation (RFA). Methods This is a prospective, observational study on GCLM patients with 1–3 liver metastases. The primary gastric lesions were thoroughly resected and any case that exhibited extra-hepatic metastasis was excluded. A 1:2:2 propensity score-matching analysis was performed using a logistic regression model on the HIFU group, best supportive care (BSC) group, and palliative chemotherapy (PC) group. The primary endpoints include progression-free survival (PFS) and overall survival (OS). Results Forty patients were finally included, there were 8 cases in HIFU group, 16 cases in BSC group, and 16 cases in PC group. The median follow-up time for the entire cohort was 10 months. The median PFS was 16.5 months in HIFU group, 2 months in BSC group, and 5 months in PC group. The median OS was 27.5 months in the HIFU group, 7 months in the BSC group, and 11.5 months in the PC group. Additionally, no grade 3 or higher adverse events occurred in the HIFU group. Conclusion The results of this study showed that HIFU treatment could improve the long-term prognosis of GCLM patients without a significant increase in the occurrence of adverse events. Compared with PC and BSC, HIFU is the preferred treatment option when GCLM patients without extra-hepatic metastasis are unable to undergo either surgery or RFA.

Hepatic resection for synchronous hepatic metastasis from gastric cancer

2013 ◽  
Vol 39 (7) ◽  
pp. 694-700 ◽  
Author(s):  
J.-L. Qiu ◽  
M.-G. Deng ◽  
W. Li ◽  
R.-H. Zou ◽  
B.-K. Li ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Hepatic Resection ◽  
Hepatic Metastasis
Sign in / Sign up

Export Citation Format

Share Document